H

Heart House Research Foundation | Springfield, OH

Research site

(Unclaimed)

Location

100 West McCreight Avenue, Suite 150, Springfield, Ohio, United States of America

Site insights

Top conditions

Top treatments

sodium

Etripamil

Inclisiran

Aspirin

losartan

Iron

Evolocumab

lisinopril

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 12 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting

Primary Prevention of Atherosclerotic Cardiovascular Disease

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Drug: Placebo in 1.5ml

Locations recently updated

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous co...

Enrolling

Peripheral Endovascular Intervention

Percutaneous Coronary Intervention

Drug: Normal Saline (Placebo)

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Inclisiran sodium 300 mg